Ovoca Bio plc’s goal is to bring value to its Shareholders through selective investment in pharmaceutical and biotechnology development opportunities. 
In 2018 Ovoca Bio made its first investment in Ivix Ltd with its highly promising clinical stage asset. Ivix Ltd is developing a new proprietary drug for female sexual dysfunction, an area of significant unmet medical need. The magnitude of demand for treatments for female sexual dysfunction has only recently been recognized; it has the potential to become a substantial pharmaceutical market. At present, there are only a few options available for treating female sexual dysfunction, all with significant shortcomings. The observed efficacy and safety profile of Ivix’ drug candidate suggests it is capable of becoming a market leader in this therapeutic area. 



March 25, 2019

Primary Endpoints Met in Libicore Phase III Study

December 31, 2018

Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

October 10, 2018

Ovoca is pleased to announce that IVIX has signed an agreement with Biopharma Excellence GmbH (Germany), an experienced biopharmaceutical drug development consultancy firm, to provide regulatory affairs services.